| Literature DB >> 30553769 |
Marie-Therese Rached1, Steven J Millership1, Silvia M A Pedroni1, Agharul I Choudhury2, Ana S H Costa3, Darran G Hardy1, Justyna A Glegola2, Elaine E Irvine2, Colin Selman4, Megan C Woodberry2, Vijay K Yadav5, Sanjay Khadayate2, Antonio Vidal-Puig6, Samuel Virtue7, Christian Frezza3, Dominic J Withers8.
Abstract
OBJECTIVE: Sympathetic nervous system and immune cell interactions play key roles in the regulation of metabolism. For example, recent convergent studies have shown that macrophages regulate obesity through brown adipose tissue (BAT) activation and beiging of white adipose tissue (WAT) via effects upon local catecholamine availability. However, these studies have raised issues about the underlying mechanisms involved including questions regarding the production of catecholamines by macrophages, the role of macrophage polarization state and the underlying intracellular signaling pathways in macrophages that might mediate these effects.Entities:
Keywords: BAT; Inflammation; Irs2; Macrophage; Obesity; Sympathetic neurons
Mesh:
Substances:
Year: 2018 PMID: 30553769 PMCID: PMC6358539 DOI: 10.1016/j.molmet.2018.11.010
Source DB: PubMed Journal: Mol Metab ISSN: 2212-8778 Impact factor: 7.422
Figure 1Physiological parameters in mice fed chow or HFD. (A) Energy expenditure (EE) in 8-week old control and Irs2 males during both the day and night cycles (n = 22–26). (B, C) Percentage fat mass (B) and percentage lean mass (C) in 23 weeks old control and Irs2 male mice on chow diet (n = 23–24). (D) Blood glucose levels in 8-week old control and Irs2 female mice following an overnight fast (n = 20). (E) Serum insulin levels from 8-week old control and Irs2 female mice following an overnight fast (n = 12–20). (F) Glucose tolerance in overnight fasted 8-week old female control and Irs2 mice (n = 8–9). Inset shows means of area under the curve (AUC) for both genotypes. (G) Body weight of control and Irs2 females fed either chow or high fat diet (HFD) from 8 weeks of age for 15 weeks (n = 8–11 for chow and n = 23 for HFD). (H, I) Percentage fat mass (H) and percentage lean mass (I) in 23-week old control and Irs2 female mice fed HFD for 15 weeks (n = 23). (J) Serum leptin levels following an overnight fast in control and Irs2 female fed HFD for 15 weeks (n = 10–12). (K) Energy expenditure (EE) values normalized to body weight in 23-week old control and Irs2 females fed HFD for 15 weeks (n = 18–20). (L, M) Blood glucose (L) and serum insulin levels (M) in overnight fasted 16-week old control and Irs2 females fed HFD for 8 weeks (n = 20–23). (N) Glucose tolerance in 6-hour fasted 16-week old control and Irs2 female mice fed HFD for 8 weeks (n = 21). Inset shows means of area under the curve (AUC) for both genotypes. (O) Homeostatic model assessment for insulin resistance (HOMA-IR) calculated from fasted blood glucose and serum insulin levels from mice in L and M (n = 20). In all panels, data presented are mean ± SEM with Student's t test for all panels except F, G and O, where ANOVA with repeated measure was used. (*P < 0.05, **P < 0.01 and ***P < 0.001 relative to control mice).
Figure 2Characterization of bone marrow derived macrophages (BMDM) from mice. (A) Quantification of MAC2 positive cells as percentage of total cell number in perigonadal white adipose tissue of control and Irs2 mice on chow (n = 8–9) or high fat diet (HFD) (n = 5). Representative images are shown in the right-hand panel, with arrows indicating the presence of macrophage crown-like structures visualized by MAC2 immunohistochemical staining. Scale bar = 500 μm. (B–E) Quantitative RT-PCR analysis of mRNA levels of M2 markers in control and Irs2 BMDM treated with vehicle or interleukin 4 (IL4, 10 ng/ml, 24 h). Hprt mRNA expression was used as an internal control and data are represented relative to control/vehicle (n = 4–7). (F–I) Analysis of mRNA levels of M1 inflammatory markers with LPS treatment (100 ng/ml, 24 h) (n = 4–6). (J, K) Arg1 and Inos mRNA levels in control and Irs2 adipose tissue macrophages (ATM) isolated from HFD-fed mice. Data are average of two independent RT-PCR experiments and ATMs were collected from a pool of 3–6 mice on HFD in each experiment (n = 6–12 mice per genotype total). In all panels, data presented are mean ± SEM with statistical analysis by ANOVA (A–I) or Student's t test (J, K). (*P < 0.05, **P < 0.01 and ***P < 0.001, relative to control BMDM/control BMDM with vehicle treatment).
Figure 3Assessment of brown adipose tissue function in mice. (A) Representative hematoxylin and eosin (H&E) staining of interscapular brown adipose tissue (BAT) from control and Irs2 mice fed either chow (top panel) or high fat diet (HFD) (lower panel) (n = 4 per group). Scale bar = 500 μm. (B) Quantitative RT-PCR analysis of mRNA levels of BAT genes in Irs2 relative to control mice on chow diet. Gapdh mRNA expression was used as an internal control (n = 6–8). (C) Analysis of mRNA levels as in B of brown adipose genes in inguinal WAT (iWAT) of Irs2 relative to control mice on chow diet. Gapdh mRNA expression was used as an internal control (n = 9–11). (D) Representative H&E staining (top panel) and immunostaining of UCP1 (lower panel) in iWAT of control and Irs2 chow-fed mice (n = 4). Scale bar = 500 μm. (E) Norepinephrine levels in non-conditioned medium (Control medium) and BMDM-conditioned medium (BMDM-CM) with vehicle, IL4 and LPS treatment. Lysates of mouse adrenal gland were used as a positive control (n = 4 per group). (F, G) Quantitative RT-PCR analysis of Th (F) and Dbh (G) mRNA levels measured in BMDM relative to adrenal gland, both from control mice. Hprt mRNA expression was used as an internal control (n = 7). (H) Tyrosine hydroxylase (Th) mRNA levels in BAT from Irs2 relative to control mice. Gapdh mRNA expression was used as an internal control (n = 6–8). (I, images) TH immunostaining (green) in BAT sections from control and Irs2 mice. DAPI was used to visualize nuclei (blue). Scale bar = 50 μm. (I, bar chart) Quantification of percentage TH density in BAT sections (n = 3–4 mice/group and 6–12 fields of view per mouse). (J) Norepinephrine levels normalized to total protein content in BAT from control and Irs2 mice (n = 16). In all panels, data presented are mean ± SEM with statistical analysis by Student's t test. (*P < 0.05, **P < 0.01 and ***P < 0.001 relative to control mice).
Figure 4mRNA sequencing analysis of control and BMDM. (A) Heat map showing differentially regulated genes in Irs2 vs control BMDM following 24 h LPS treatment from RNA-seq analysis, including a large subset of downregulated pro-inflammatory genes in the Irs2/LPS group (n = 4 for control, 3 for Irs2). (B) Gene ontology (GO) categories of top 200 significantly regulated genes in Irs2 BMDM following 24 h treatment with LPS. (C) Differential expression of NLRP3 inflammasome-associated genes in LPS-treated Irs2 vs LPS-treated control BMDM. Log2 fold change for each gene is shown in its respective bar. (D) Differential expression of Gdf3 in both vehicle and LPS-treated Irs2 relative to control BMDM with respective treatments. Log2 fold change is shown in each respective bar. (E) GO categories with significant enrichment related to nerve growth and function in Irs2 relative to control BMDM with either vehicle, LPS or IL4 (overnight) treated conditions. (F) Heat map showing upregulated neuronal-associated genes (secreted and cell surface proteins involved in cell adhesion and cell-to-cell interactions) in Irs2 vs control BMDM under various conditions. (G) GO categories with significant enrichment in Irs2 relative to control BMDM under various conditions. (H) Gene set enrichment analysis showing increase of microglial markers in IL4-treated Irs2 relative to IL4-treated control BMDM. (I) Differential expression of β2 adrenergic genes Adrb2 and Adrbk2 in IL4-treated Irs2 relative to IL4-treated control BMDM. Log2 fold change for each gene is shown in its respective bar. In panels B–E and also G and I, P values for GO enrichment categories or individual genes are shown, calculated as described in the methods (section 2.8).
| List of probes used in RT-PCR. (TaqMan, Applied Biosystems, all | |
|---|---|
| Interleukin 1 beta | Mm01336189_m1 |
| Interleukin 6 | Mm00446190_m1 |
| Inducible nitric oxide synthase | Mm00440502_m1 |
| Tumor necrosis factor alpha | Mm00443258_m1 |
| Arginase 1 | Mm00475988_m1 |
| Chitinase 3-like-3 | Mm04213363_m1 |
| Mannose receptor 1 | Mm00485148_m1 |
| C-type lectin domain family 10 member A | Mm00546124_m1 |
| Hypoxanthine phosphoribosyltransferase | Mm03024075_m1 |
| Uncoupling protein 1 | Mm01244861_m1 |
| Glyceraldehyde-3-phosphate dehydrogenase | Mm99999915_g1 |
| Peroxisome proliferator-activated receptor gamma, coactivator 1 alpha | Mm01208835_m1 |
| Tyrosine hydroxylase | Mm00447557_m1 |
| Cell death-inducing DNA fragmentation factor, alpha subunit-like effector A | Mm00432554_m1 |
| Insulin receptor substrate 2 | Mm03038438_m1 |
| Dopamine beta hydroxylase | Mm00460472_m1 |